32 results
424B5
MYGN
Myriad Genetics, Inc.
13 Nov 23
Prospectus supplement for primary offering
6:02am
of borrowings under our ABL Facility. Therefore, Goldman Sachs & Co. LLC and Wells Fargo Securities, LLC have a “conflict of interest” with us in regard … have a “conflict of interest” in regard to this offering under FINRA Rule 5121. Accordingly, this offering is being made in compliance
424B5
MYGN
Myriad Genetics, Inc.
8 Nov 23
Prospectus supplement for primary offering
4:05pm
and Wells Fargo Securities, LLC have a “conflict of interest” in regard to this offering under Rule 5121 of the Financial Industry Regulatory … to the repayment of borrowings under our ABL Facility. Therefore, Goldman Sachs & Co. LLC and Wells Fargo Securities, LLC have a “conflict of interest” with us
8-K
EX-10.1
98sj 1w8w
27 Jul 22
Entry into a Material Definitive Agreement
4:11pm
8-K
EX-10.1
wjej08lx3ld5
23 Feb 21
Company Continues to Execute Strategic Transformation Plan
4:15pm
8-K
EX-3.1
2nwu2ea
15 Oct 20
Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate
7:18am